Article
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Cell - 31 May 2018
Wang Liqin, Leite de Oliveira Rodrigo, Huijberts Sanne, Bosdriesz Evert, Pencheva Nora, Brunen Diede, Bosma Astrid, Song Ji-Ying, Zevenhoven John, Los-de Vries G Tjitske, Horlings Hugo, Nuijen Bastiaan, Beijnen Jos H, Schellens Jan H M, Bernards Rene
Abstract excerpt
BRAF(V600E) mutant melanomas treated with inhibitors of the BRAF and MEK kinases almost invariably develop resistance that is frequently caused by reactivation of the mitogen activated protein kinase (MAPK) pathway. To identify novel treatment options for such patients, we searched for acquired vulnerabilities of MAPK inhibitor-resistant melanomas. We find that resistance to BRAF+MEK inhibitors is associated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.